Total submissions: 8
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000226242 | SCV000283058 | uncertain significance | Ataxia-telangiectasia syndrome | 2022-10-31 | criteria provided, single submitter | clinical testing | This sequence change replaces arginine, which is basic and polar, with glycine, which is neutral and non-polar, at codon 2506 of the ATM protein (p.Arg2506Gly). This variant is present in population databases (rs200441272, gnomAD 0.06%). This variant has not been reported in the literature in individuals affected with ATM-related conditions. ClinVar contains an entry for this variant (Variation ID: 236775). Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be tolerated. RNA analysis performed to evaluate the impact of this missense change on mRNA splicing indicates it does not significantly alter splicing (Invitae). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Gene |
RCV000236767 | SCV000292894 | uncertain significance | not provided | 2024-05-09 | criteria provided, single submitter | clinical testing | In silico analysis indicates that this missense variant does not alter protein structure/function; Reported in a patient with a family history of breast cancer (PMID: 35534704); This variant is associated with the following publications: (PMID: 23532176, 35534704) |
Ambry Genetics | RCV000570854 | SCV000660522 | uncertain significance | Hereditary cancer-predisposing syndrome | 2024-03-13 | criteria provided, single submitter | clinical testing | The p.R2506G variant (also known as c.7516A>G), located in coding exon 50 of the ATM gene, results from a A to G substitution at nucleotide position 7516. This variant impacts the first base pair of coding exon 50. The arginine at codon 2506 is replaced by glycine, an amino acid with dissimilar properties. This amino acid position is not well conserved in available vertebrate species. In addition, this alteration is predicted to be tolerated by in silico analysis. Based on the available evidence, the clinical significance of this alteration remains unclear. |
Color Diagnostics, |
RCV000570854 | SCV000903864 | uncertain significance | Hereditary cancer-predisposing syndrome | 2023-05-05 | criteria provided, single submitter | clinical testing | This missense variant replaces arginine with glycine at codon 2506 of the ATM protein. Computational prediction suggests that this variant may not impact protein structure and function (internally defined REVEL score threshold <= 0.5, PMID: 27666373). To our knowledge, functional studies have not been reported for this variant. This variant has not been reported in individuals affected with ATM-related disorders in the literature. This variant has been identified in 17/281938 chromosomes in the general population by the Genome Aggregation Database (gnomAD). The available evidence is insufficient to determine the role of this variant in disease conclusively. Therefore, this variant is classified as a Variant of Uncertain Significance. |
Sema4, |
RCV000570854 | SCV002538049 | uncertain significance | Hereditary cancer-predisposing syndrome | 2021-12-09 | criteria provided, single submitter | curation | |
Prevention |
RCV004547577 | SCV004115291 | uncertain significance | ATM-related disorder | 2023-09-08 | criteria provided, single submitter | clinical testing | The ATM c.7516A>G variant is predicted to result in the amino acid substitution p.Arg2506Gly. To our knowledge, this variant has not been reported in the literature. This variant is reported in 0.060% of alleles in individuals of African descent in gnomAD (http://gnomad.broadinstitute.org/variant/11-108202171-A-G). It is interpreted as uncertain significance in ClinVar (https://preview.ncbi.nlm.nih.gov/clinvar/variation/236775/). At this time, the clinical significance of this variant is uncertain due to the absence of conclusive functional and genetic evidence. |
Baylor Genetics | RCV003463633 | SCV004207573 | uncertain significance | Familial cancer of breast | 2024-03-17 | criteria provided, single submitter | clinical testing | |
Genome |
RCV001535479 | SCV001749412 | not provided | Ataxia-telangiectasia syndrome; Malignant tumor of breast | no assertion provided | phenotyping only | Variant interpreted as Uncertain significance and reported on 04-20-2020 by Invitae. GenomeConnect-Invitae Patient Insights Network assertions are reported exactly as they appear on the patient-provided report from the testing laboratory. Registry team members make no attempt to reinterpret the clinical significance of the variant. Phenotypic details are available under supporting information. |